BIOCYTOGEN-B Surges Over 12% in Intraday Trading, Completes Localized Deployment of AI-Driven Antibody Drug Development Platform

Deep News01-14

BIOCYTOGEN-B (02315) rose more than 12% during intraday trading, accumulating a gain of approximately 30% over the past three days. At the time of writing, the stock was up 7.58% to HK$46, with a turnover of HK$53.8796 million.

On January 13, Biocytogen stated on an interactive platform that the company has completed the localized deployment of its AI-driven antibody drug development platform and achieved full synergy with its core business, the "Thousand Mice Ten Thousand Antibodies" initiative. Through this localized AI deployment, the company is building an AI agent for antibody drug development. As the deep integration of the "Thousand Mice Ten Thousand Antibodies" initiative and the AI system continues to advance, the company will provide global pharmaceutical companies with more efficient R&D tools and a richer library of antibody molecules, helping partner companies improve the R&D efficiency of preclinical PCC molecules, which will also propel the antibody discovery business into a new stage of development.

Furthermore, the company recently announced with Acepodia that the two parties have entered into an option and license agreement, aiming to conduct a systematic evaluation of bispecific antibody-drug conjugate (BsADC) projects through a structured assessment mechanism, thereby further accelerating the development process of bispecific antibody-dual drug conjugates (BsAD2C).

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1148865982?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-14 10:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1148865982","market":"other","top_or_hot":-1,"title":"BIOCYTOGEN-B Surges Over 12% in Intraday Trading, Completes Localized Deployment of AI-Driven Antibody Drug Development Platform","media":"Deep News","content":"<p>BIOCYTOGEN-B (02315) rose more than 12% during intraday trading, accumulating a gain of approximately 30% over the past three days. At the time of writing, the stock was up 7.58% to HK$46, with a turnover of HK$53.8796 million.</p>\n<p>On January 13, Biocytogen stated on an interactive platform that the company has completed the localized deployment of its AI-driven antibody drug development platform and achieved full synergy with its core business, the \"Thousand Mice Ten Thousand Antibodies\" initiative. Through this localized AI deployment, the company is building an AI agent for antibody drug development. As the deep integration of the \"Thousand Mice Ten Thousand Antibodies\" initiative and the AI system continues to advance, the company will provide global pharmaceutical companies with more efficient R&D tools and a richer library of antibody molecules, helping partner companies improve the R&D efficiency of preclinical PCC molecules, which will also propel the antibody discovery business into a new stage of development.</p>\n<p>Furthermore, the company recently announced with Acepodia that the two parties have entered into an option and license agreement, aiming to conduct a systematic evaluation of bispecific antibody-drug conjugate (BsADC) projects through a structured assessment mechanism, thereby further accelerating the development process of bispecific antibody-dual drug conjugates (BsAD2C).</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BIOCYTOGEN-B Surges Over 12% in Intraday Trading, Completes Localized Deployment of AI-Driven Antibody Drug Development Platform</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBIOCYTOGEN-B Surges Over 12% in Intraday Trading, Completes Localized Deployment of AI-Driven Antibody Drug Development Platform\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time\">2026-01-14 10:17</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>BIOCYTOGEN-B (02315) rose more than 12% during intraday trading, accumulating a gain of approximately 30% over the past three days. At the time of writing, the stock was up 7.58% to HK$46, with a turnover of HK$53.8796 million.</p>\n<p>On January 13, Biocytogen stated on an interactive platform that the company has completed the localized deployment of its AI-driven antibody drug development platform and achieved full synergy with its core business, the \"Thousand Mice Ten Thousand Antibodies\" initiative. Through this localized AI deployment, the company is building an AI agent for antibody drug development. As the deep integration of the \"Thousand Mice Ten Thousand Antibodies\" initiative and the AI system continues to advance, the company will provide global pharmaceutical companies with more efficient R&D tools and a richer library of antibody molecules, helping partner companies improve the R&D efficiency of preclinical PCC molecules, which will also propel the antibody discovery business into a new stage of development.</p>\n<p>Furthermore, the company recently announced with Acepodia that the two parties have entered into an option and license agreement, aiming to conduct a systematic evaluation of bispecific antibody-drug conjugate (BsADC) projects through a structured assessment mechanism, thereby further accelerating the development process of bispecific antibody-dual drug conjugates (BsAD2C).</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0216","symbol_name":"研究试验","start_time":0,"source_url":"","article_id":"1148865982","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1148865982","pubTimestamp":1768357058,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"BIOCYTOGEN-B (02315) rose more than 12% during intraday trading, accumulating a gain of approximately 30% over the past three days. At the time of writing, the stock was up 7.58% to HK$46, with a...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688796":"百奥赛图","BK0216":"研究试验","BK1161":"生物科技","02315":"百奥赛图-B"},"translate_title":"百奥赛图-B盘中大涨超12%，完成AI驱动抗体药物开发平台本地化部署","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688796":1,"02315":1},"content_text":"BIOCYTOGEN-B (02315) rose more than 12% during intraday trading, accumulating a gain of approximately 30% over the past three days. At the time of writing, the stock was up 7.58% to HK$46, with a turnover of HK$53.8796 million.\nOn January 13, Biocytogen stated on an interactive platform that the company has completed the localized deployment of its AI-driven antibody drug development platform and achieved full synergy with its core business, the \"Thousand Mice Ten Thousand Antibodies\" initiative. Through this localized AI deployment, the company is building an AI agent for antibody drug development. As the deep integration of the \"Thousand Mice Ten Thousand Antibodies\" initiative and the AI system continues to advance, the company will provide global pharmaceutical companies with more efficient R&D tools and a richer library of antibody molecules, helping partner companies improve the R&D efficiency of preclinical PCC molecules, which will also propel the antibody discovery business into a new stage of development.\nFurthermore, the company recently announced with Acepodia that the two parties have entered into an option and license agreement, aiming to conduct a systematic evaluation of bispecific antibody-drug conjugate (BsADC) projects through a structured assessment mechanism, thereby further accelerating the development process of bispecific antibody-dual drug conjugates (BsAD2C).","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1148865982","isCrawlerRequest":true}